Press release



IBA Provides Faster And Safer Radiation Therapy (RT) Plan Verification With The Release Of Next Generation OmniPro I'mRT ⁺ Software

The new Central Database enables consistent, thus safer management of patient treatments.

Hospital network-wide access allows users to connect and share data across the RT department providing more flexibility, efficiency, and reducing cost.

Schwarzenbruck, Germany, January 22nd, 2014 – IBA (Ion Beam Applications S.A.), the global high-tech leader in the next generation of proton therapy solutions and radiation therapy dosimetry for the treatment of cancer, announces the release of a completely new solution for IMRT and Rotational pre-treatment plan verification: The OmniPro I'mRT ⁺ software. This solution sets a new efficiency standard within IBA's software family.

Clear software workflow, as well as intuitive and easy-to-use controls, enable for faster operations. The new Central Database access via the hospital network makes the entire plan verification process easier and much more efficient compared to previous solutions. The different plan verification steps – Import, Measure, Verify, and Report (including approvals) - can now be managed through the network. This allows physicists and dosimetrists to choose the most efficient QA workflow for not only their department but also the connected satellite hospitals. All patients, projects, and equipment data are stored on the central database providing increased data safety and integrity.

"The entire software package has been completely redesigned and re-engineered from the ground up to maximize efficiency and streamline the IMRT QA process", says James P. Nunn, MS, CHP, DABR, Senior Medical Physicist at Lewis Gale Regional Cancer Center, Pulaski, USA. "The elimination of repetitive steps allows me to greatly reduce the time required for patient plan verification. For example, I save Linac time by preparing all patient data beforehand in my office. During measurements I simply load the patient data and start right away using my MatriXX detector. All in all, a nice advancement over the previous software, giving me more efficiency and flexibility for my plan verification."

"We are excited to launch the new OmniPro I'mRT⁺, a software that provides additional value for our existing MatriXX users as well as for all physicists that require a sophisticated, jet-fast solution for pre-treatment IMRT and rotational plan verification. The software was entirely redeveloped based on input from our vast user group, and with a focus on workflow efficiency", remarked Ralf Schira, Vice President of Marketing for IBA Dosimetry. "The result is a tool that fulfills the needs of a modern and busy radiation therapy department."

About IBA

IBA (Ion Beam Applications S.A.) is a cancer diagnostics and treatment equipment company, and the worldwide technology leader in the field of proton therapy, the most advanced form of radiotherapy available today. The Company's primary expertise lies in the development of next generation proton therapy technologies that provide oncology care providers with premium quality services and equipment. IBA's proton therapy solutions are scalable and adaptable, offering universal full scale proton therapy centers as well as next generation compact, single room systems.

IBA Dosimetry GmbH Bahnhofstraße 5 | 90592 Schwarzenbruck | Deutschland | Tel.: +49 9128 607 0 | Fax: +49 9128 607 10 | Register-Ger. Nürnberg, HR B 4262 | WEEE-Reg.-Nr. DE 65960409 | Geschäftsführer: Olivier Legrain, Rob Plompen | info@iba-dosimetry.com | www.iba-dosimetry.com

Press release



IBA also focuses on the development and supply of dosimetry solutions for Quality Assurance of medical equipment and increased patient safety as well as particle accelerators for medical and industrial applications.

Headquartered in Belgium and employing more than 1,000 people worldwide, IBA currently has installed systems across Europe and the US and is expanding into emerging markets. The Company is focused on building sustainable global growth for investors by providing solutions in the fight against cancer.

IBA is listed on the pan-European stock exchange EURONEXT. (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB) and more information can be found at: www.iba-worldwide.com

Media Contact: Suzanne Shankle Marketing Specialist IBA Dosimetry 3150 Stage Post Drive, Suite 110 Bartlett, TN 38133 Tel: (901) 386-2242 Suzanne.shankle@iba-group.com http://www.iba-dosimetry.com

Press release |January 22, 2014

###